Akebia Therapeutics, Inc.
No SEC Form 4 filings for $AKBA in the last 30 days.
See all $AKBA insider activity →Akebia Therapeutics, Inc. (AKBA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026pr.htm EX-99.1 Document Exhibit 99.1 Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights Q2 2026 Vafseo® (vadadustat) net product revenues grew to $21.3 million; more than 10,500 p atients now on therapy Advancement of rare ki
Akebia Therapeutics, Inc. (AKBA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. akba-20260617 0001517022 FALSE 0001517022 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ FORM 8-K _____________________ CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date
Akebia Therapeutics is seeking shareholder approval to significantly increase its authorized common shares from 350 million to 500 million, and total capital stock from 375 million to 525 million, at its virtual 2026 annual meeting on June 17, 2026. This move aims to provide the company with greater flexibility for future financing, strategic deals, and equity incentives without requiring further charter amendments. Shareholders will also vote on director elections, executive compensation, its frequency, and the ratification of Ernst & Young LLP as the independent auditor.
Over the past 7 days, alphai's AI scored 1 news story mentioning AKBA (Akebia Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent AKBA coverage spans financial news, earnings and corporate actions.
Near-term trading focus is on Vafseo commercial momentum and the VOICE safety readout, offset by Auryxia revenue decline and higher operating costs.
The 8-K discloses shareholder-approved increases to authorized capital, which can enable future equity issuance and dilute holders.
The proposed increase in authorized shares by Akebia Therapeutics may lead to potential dilution of existing shares, affecting stock price and investor sentiment.
The initiation of a Phase 2 trial for praliciguat targeting FSGS, a rare kidney disease with no current approved treatments, presents a potential growth catalyst for Akebia Therapeutics (AKBA). The news indicates progress in drug development, which could positively influence the company's valuation.
The surge in implied volatility for AKBA options signals increased investor interest and potential upcoming stock movement, but the current data suggests limited immediate price impact.
alphai scores every news story that mentions AKBA with an AI model for sentiment and relevance, and aggregates insider trades from Akebia Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Akebia Therapeutics, Inc. (AKBA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026pr.htm EX-99.1 Document Exhibit 99.1 Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights Q2 2026 Vafseo® (vadadustat) net product revenues grew to $21.3 million; more than 10,500 p atients now on therapy Advancement of rare ki
6 min readAkebia Therapeutics, Inc. (AKBA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. akba-20260617 0001517022 FALSE 0001517022 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ FORM 8-K _____________________ CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date
2 min readAkebia Therapeutics is seeking shareholder approval to significantly increase its authorized common shares from 350 million to 500 million, and total capital stock from 375 million to 525 million, at its virtual 2026 annual meeting on June 17, 2026. This move aims to provide the company with greater flexibility for future financing, strategic deals, and equity incentives without requiring further charter amendments. Shareholders will also vote on director elections, executive compensation, its frequency, and the ratification of Ernst & Young LLP as the independent auditor.
4 min readAkebia Therapeutics has announced that the first patient has been dosed in a Phase 2 clinical trial for praliciguat, a soluble guanylate cyclase (sGC) stimulator. This drug is being evaluated for the treatment of biopsy-confirmed FSGS, a rare kidney disease, with potential future applications for other rare podocytopathies. There are currently no approved treatments for FSGS, which impacts approximately 40,000 patients in the U.S., and praliciguat has shown no significant safety issues in previous Phase 1 and 2 studies.
2 min readInvestors need to pay close attention to AKBA stock based on the movements in the options market lately.
3 min readThe heavy selling pressure might have exhausted for Akebia Therapeutics (AKBA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend ...
3 min readCAMBRIDGE, Mass., Nov. 06, 2025 ( GLOBE NEWSWIRE ) -- Akebia Therapeutics®, Inc. ( NASDAQ:AKBA ) , a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the presentation of a post-hoc win odds analysis of all-cause mortality and ...
2 min readThe most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
3 min readAkebia Therapeutics Inc. ( NASDAQ:AKBA ) stock is trading lower on Wednesday. The kidney disease company met with the U.S.
2 min readShares of Teradyne Inc ( NASDAQ:TER ) rose sharply in today's pre-market trading after the company announced better-than-expected third-quarter results and issued strong forecast for the current quarter. Teradyne reported quarterly earnings of 85 cents per share which beat the analyst ...
4 min read
